Magenta Therapeutics, Inc. (NASDAQ: MGTA)

Engel Law PLLC is investigating whether fair value to Magenta shareholders will result from the proposed merger between Magenta Therapeutics, Inc. (NASDAQ: MGTA) and Dianthus Therapeutics, Inc., pursuant to which pre-mergerDianthus stockholders are expected to own approximately 78.7% of the combined company and pre-merger Magenta stockholders are expected to own approximately 21.3% of the combined company.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Magenta Therapeutics, Inc.

MM slash DD slash YYYY